Mereo BioPharma Group plc

General Information

(Note: “Our ordinary shares have been traded on AIM, a market of the London Stock Exchange, under the symbol “MPH” since June 9, 2016. On April 4, 2018, the last reported sale price of our ordinary shares on AIM was £3.14 per ordinary share (equivalent to $17.62 per ADS based on an exchange rate of £1.00 to $1.4027).”)

 We are a multi-asset biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases. Our portfolio consists of four clinical-stage product candidates, each of which we acquired from large pharmaceutical companies. We are developing BPS-804 for the treatment of osteogenesis imperfecta, or OI; AZD-9668 for the treatment of severe alpha-1 antitrypsin deficiency, or AATD; BCT-197 for the treatment of acute exacerbations of chronic obstructive pulmonary disease, or AECOPD, and BGS-649 for the treatment of hypogonadotropic hypogonadism, or HH, in obese men.


Employees: 33
Founded: 2015
Contact Information
Address Fourth Floor, One Cavendish Place, London, W1G 0QF, United Kingdom
Phone Number +44 (0) 33 3023 7300.
Web Address
View Prospectus: Mereo BioPharma Group plc
Financial Information
Market Cap $383.2mil
Revenues $0 mil (last 12 months)
Net Income $-52.5 mil (last 12 months)
IPO Profile
Symbol MREO
Exchange NASDAQ
Shares (millions): 2.8
Price range $17.62 - $17.62
Est. $ Volume $49.9 mil
Manager / Joint Managers Cowen/ BMO Capital Markets/ RBC Capital Markets
CO-Managers JMP Securities/ Cantor Fitzgerald Europe
Expected To Trade:
Status: Postponed
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change